Abstract
Patients with BRAF V600E mutation-positive melanoma who were assigned to 150 mg dabrafenib twice daily combined with 2 mg trametinib once daily in a phase I/II study showed a median overall survival (OS) of 23.8 months, compared with 20.2 months for patients assigned to dabrafenib alone [hazard ratio (HR)=0.73, 95% confidence interval (CI) 0.43-1.24; data cutoff March 2013], on the basis of an intention-to-treat analysis. Because patients assigned to dabrafenib monotherapy were allowed to switch to combination therapy upon disease progression, we attempted to adjust for confounding effects on OS. Randomization-based adjustment methods, Rank Preserving Structural Failure Time Models and the Iterative Parameter Estimation algorithm, were used. Two analyses, 'treatment group' (assumes that treatment effect continues beyond treatment discontinuation) and 'on treatment' (assumes that the treatment effect disappears upon treatment discontinuation), were used to test assumptions on the durability of the treatment effect. A total of 45/54 (83%) patients assigned to dabrafenib monotherapy switched to the trametinib/dabrafenib combination. Adjusted OS HRs ranged from 0.47 to 0.50, depending on the analysis, compared with the unadjusted O...Continue Reading
References
Apr 1, 1993·Controlled Clinical Trials·S D Mark, J M Robins
Sep 25, 1999·Statistics in Medicine·I R WhiteJ H Darbyshire
Sep 14, 2000·Biometrics·J M Robins, D M Finkelstein
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Sep 3, 2002·Statistics in Medicine·Michael Branson, John Whitehead
Jun 24, 2004·Statistics in Medicine·Takuhiro Yamaguchi, Yasuo Ohashi
Nov 18, 2005·The New England Journal of Medicine·John A CurtinBoris C Bastian
Jun 10, 2010·British Journal of Cancer·K H T ParaisoK S M Smalley
Dec 24, 2010·Science Signaling·Oliver E SturmWalter Kolch
Jan 13, 2011·BMC Medical Research Methodology·James P MordenAllan J Wailoo
Feb 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marco ColleoniAron Goldhirsch
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Huan JinPaul E Goss
Dec 20, 2011·Cancer·John A JakobMichael A Davies
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Jul 19, 2012·The Lancet Oncology·Gerald S FalchookLeslie A Fecher
Oct 2, 2012·The New England Journal of Medicine·Keith T FlahertyJeffrey Weber
Oct 19, 2013·Pharmaceutical Statistics·Claire WatkinsElaine J Wright
Jan 23, 2014·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Nicholas R LatimerMichael J Campbell
Mar 7, 2014·PharmacoEconomics·K Jack IshakJuan Valle
Sep 23, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linus JönssonMichael Drummond
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lawrence E FlahertyVernon K Sondak
Nov 19, 2014·British Journal of Haematology·Gareth MorganMeletios A Dimopoulos
Citations
Nov 20, 2016·Therapeutic Drug Monitoring·Huu H HuynhSamia Mourah
Nov 23, 2019·Targeted Oncology·Susan FeyerabendKarim Fizazi
Jan 1, 2016·Oncology and Therapy·Jordan AmdahlThomas E Delea
Mar 22, 2020·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Thomas R SullivanJonathan Karnon
Feb 25, 2021·Melanoma Research·Ferdy J LejeunePatrick A Riley
Jul 20, 2021·Clinical Lymphoma, Myeloma & Leukemia·Raheel SiddiquiFaiz Anwer